The global DNA encoded library market size is expected to be worth USD 1.06 Billion in 2025. It can balloon to an outsized valuation of USD 3.11 Billion by 2032. The market is anticipated to exhibit a CAGR of 16.6% during the forecast period (2025-2032).
The expansion of DNA encoded libraries (DEL) is driven by increasing R&D investments, applications in target validation, and the emergence of new biologics. The focus of pharmaceutical companies towards new screening techniques can drive the market growth over the forecast period.
However, the mislabeling of small molecules with DNA encoded libraries, which could hinder scientific breakthroughs, can hamper the market growth.
Key Market Insights
The DNA encoded library market growth is driven by the growing need for new active compounds, innovative drug discovery approaches, and advancements in biotechnology.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/global-dna-encoded-library-market
DNA Encoded Library Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 1.06 Billion |
|
Estimated Value by 2032 |
USD 3.11 Billion |
|
Growth Rate |
16.6% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Therapeutic Area, Library Type, Application, and End User |
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The discovery of novel small molecules is predicted to drive the growth of the DNA encoded library market. The application of DEL for the identification of small molecule ligands for targeting of live cancer cells can open up new avenues in precision medicine. Identification of biomarkers can mark a new era in cancer therapy development.
Researchers are employing machine learning (ML) techniques in the pursuit of this discovery. The new strains of viruses require compounds that help the immune system fight external threats to the body. Use of ML can train the AI system for improving their hit validation technique. The use of ML can train the AI system to improve its hit validation technique. The identification of potential drug candidates using molecular interactions can drive market growth.
Market Opportunity: Partnership Led Expansion
Several collaborations between biotechnology firms and DEL service providers are likely to provide a prime opportunity for expansion. Companies are even outsourcing DEL services to gain a lead in their drug discovery process. For instance, ETH Zurich's Department of Biosystems Science and Engineering (D-BSSE) and the Botnar Institute of Immune Engineering IIE have established a significant long-term strategic partnership on March 20, 2025. The transformation of high-throughput screening (HTS) is expected to be driven by the use of computational biology and artificial intelligence.
Market Challenge: Mislabeling of Small Molecules to be a Setback for Drug Discovery
The mislabeling of small molecules can prove expensive to drug manufacturers. The application of machine learning to the drug discovery process has expedited it exponentially. But it has also led to the miscategorization of molecules within DNA encoded libraries. A recent study on the reliability of DNA encoded libraries by the University of Utah on July 04, 2025, revealed that they had mislabeled many good molecules as bad. This led to the dismissal of various compounds that could be used in the development of various drugs. The failure to act on these findings can be detrimental to the DNA encoded library market growth.
Analyst’s View
Recent Developments
Evotec SE, a Germany-based biotechnology company specializing in drug discovery and development, partnered with X-Chem on September 05, 2024, to strengthen its early drug discovery process. The former aims to leverage the latter’s DNA encoded library for identifying potential drug candidates.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :